Company: PACB
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001299130-25-000090
Chunk: 69

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 69
---
 employment with the Company terminated. Mr. Henry’s appointment as our interim Chief Financial Officer became effective upon her departure, and he served in such capacity until Mr. Gibson’s commencement of employment on March 31, 2025.

(2) Mr. Eidel’s last day as Chief Commercial Officer of the Company was November 15, 2024, at which time his employment with the Company terminated.

#### Executive Summary
We are a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and, ultimately, resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing technology and our Sequencing by Binding (SBB ® ) short-read sequencing technology. Our products address solutions across a broad set of applications including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Long-read sequencing was recognized by the journal Nature Methods as its “method of the year” for 2022 for its contributions to biological understanding and future potential. Long-read sequencing has been applied to produce telomere-to-telomere genomes of humans, pangenome references, and has been recognized for its ability to provide more complete views of human variation. Our focus is on creating some of the world’s most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes. Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.

Business Highlights

We have outlined below a few recent financial and operational highlights over the past year:

#### •

#### Recorded revenue of $154.0 million in 2024.
• Commercially released a revolutionary new benchtop sequencer, Vega TM and SPRQ chemistry for the Revio system.

| 2025 Proxy Statement |     | 50 |

TABLE OF CONTENTS

#### •

#### Shipped orders for 97 Revio systems in 2024.
#### •

#### Instrument revenue of $65.8 million in 2024.
#### •

#### Consumables revenue of $70.3 million in 2024.
• Service and other revenue of $17.9 million in 2024.

| 2025 Proxy Statement |